This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ellen Corenswet
Ellen B. Corenswet
Senior Counsel
New York +1 212 841 1256 Download V-card

Ellen Corenswet acts as outside corporate general counsel to emerging companies, principally in the life sciences and technology/media industries.  She also represents traditional and corporate VCs in their financings.  Ms. Corenswet's company clients range from early stage to public companies.  She makes a personal commitment to each of her clients to spend the time to understand their business and objectives and to help them understand the issues they will face.  Ms. Corenswet prides herself on the energy and enthusiasm she brings to helping her clients.  She has been recognized as a leading life sciences corporate lawyer by The Practical Law Company (PLC) and is a frequent speaker on legal panels and at conferences, particularly in the life sciences industry.  Ms. Corenswet is on the Board of National Advisors of Springboard Enterprises, Inc. and has been a long-time advisor to Springboard companies in the tech, media and life sciences sectors.  She is also on the Board of Directors of New York BIO.

Mergers & Acquisitions

  • Acorda Therapeutics, Inc., a public specialty pharmaceutical company, in its acquisition of certain marketed and development-stage assets of NeurogesX Corporation.
  • JBR Pharma, Inc., a development stage biotech company, in its sale to Lycera Corporation.
  • TrioMed Innovations Corp. in its formation, venture financing and acquisition of assets of Safe Life Corp., an anti-microbial products company.
  • Memory Pharmaceuticals Corporation in its acquisition by Hoffman-La Roche Inc.

Venture Financings

  • Johnson & Johnson Development Corporation in a preferred stock investment in a start-up biotechnology company.
  • MedImmune Ventures as the lead investor in a Series A Preferred Stock financing in G1 Therapeutics, Inc. (small molecule for use in cancer therapy).
  • AstraZeneca in its Series D Preferred Stock investment in Moderna Therapeutics, Inc. (development of messenger RNA therapeutics).
  • VantagePoint Venture Partners in numerous preferred stock financings, including Premium Power Corporation (advanced battery technology).
  • TouchTunes Interactive Networks, Inc., the largest interactive entertainment platform, in its Series E Preferred Stock financing led by 3i Corporation.
  • KitCheck, Inc. (hospital pharmacy kit processing solutions) in its Series A Preferred Stock financing.
  • Highbridge Principal Strategies in its minority investment in Revolt TV, a cable channel launched by Sean Combs.
  • Tracon Pharmaceuticals, Inc. in its recapitalization and Series A Preferred financing by Asian and European investors.


  • IPOs of Acorda Therapeutics, Inc., Memory Pharmaceuticals Corporation and

Pro Bono

  • Plan International, Inc. in its acquisition of CEDPA (Centre for Population and Development Activities).
  • Coalition for Queens, a technology initiative focused on building a tech community in Queens.
  • Best Lawyers in America, Health Care (2014)
  • PLC - Life Sciences, Which Lawyer?, Corporate (2006-2012)
  • Legal 500 US, Venture Capital & Emerging Companies (2012-2016)
  • LMG Life Sciences, "Life Science Star" (2013)